Global Age-Related Macular Degeneration Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Age-Related Macular Degeneration Market was valued at $12.3 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 7.8% CAGR, to an estimated market size of $17.9 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global Age-Related Macular Degeneration (AMD) market encompasses the pharmaceutical treatments, diagnostic tools, and management therapies for a progressive ocular disease that causes the loss of central vision. The scope includes both Wet AMD (neovascular) and Dry AMD (atrophic), specifically focusing on anti-VEGF therapies, complement inhibitors for geographic atrophy, and emerging gene therapies.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Age-Related Macular Degeneration Market in the period 2025-30:
- The primary market driver is the rapidly aging global population, with the number of individuals aged 65 and older expected to reach 1.5 billion by 2050.
- The recent approval of complement inhibitors for geographic atrophy has unlocked a massive, previously untapped revenue stream within the Dry AMD segment.
- There is a significant shift toward long-acting therapies and sustained-release drug delivery systems to reduce the high treatment burden of frequent intravitreal injections.
- Advancements in Optical Coherence Tomography (OCT) and AI-integrated retinal imaging are enabling earlier diagnosis and more precise disease monitoring.
- The emergence of biosimilars for blockbuster anti-VEGF drugs is increasing treatment accessibility while putting downward pressure on per-unit pricing.
- Ongoing research into gene therapy offers the potential for one-time treatments that could fundamentally change the standard of care for chronic AMD management.
- Rising healthcare expenditure and improved diagnostic infrastructure in emerging economies, particularly in the Asia-Pacific region, are accelerating market expansion.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Wet AMD (Neovascular)
- Dry AMD (Atrophic)